Advancing the future of obesity
We’re developing next-generation therapeutics that precisely target fat loss while protecting lean muscle mass, advancing a new era of safe, effective, and sustainable obesity care.
Our proprietary drug platform is built on next-generation GLP-1 analogs and metabolic modulators.
- Enhance fat oxidation while preserving lean mass.
- Support long-term cardiovascular and hormonal health.
- Normalize appetite signaling and glucose metabolism
Our Pipeline
We’re developing first-in-class small molecules and peptide therapeutics to unlock a healthier metabolism safely and effectively.
Phase 1
Program
INHBE (Activin E)
Indication
Obesity
Est. Ph I Initiation
Q4 2025
Modality
siRNA
Preclinical
Program
Myostatin (GDF8)
Indication
Obesity
Est. Ph I Initiation
H2 2025
Modality
Half-life extended monoclonal antibody
Join the Future of Weight Management
We are currently enrolling participants in early-stage clinical studies. If you’re living with obesity or metabolic syndrome, you may qualify to participate in our groundbreaking research.
Contact
Get in touch!
Compose the future with us
"*" indicates required fields